India to Belarus: Albendazole Export Trade Route

To import Albendazole formulations into Belarus, the following approvals and registrations are necessary:

• Registration Dossier Format: The registration dossier must be submitted in the Common Technical Document (CTD) format.

• Application Submission: Applicants are required to submit a comprehensive dossier that includes administrative information, quality data, non-clinical study reports, and clinical study reports.

• Approval Timelines: The standard timeline for the registration process is approximately 160 working days, excluding the periods for preclinical and clinical trials, remedial actions, and potential GMP inspections.

• Product Registration Fees: While specific fees are not publicly detailed, they are generally structured based on the type of registration procedure (e.g., general or simplified) and the nature of the medicinal product.

• GMP Inspection Requirements: For manufacturing facilities located in countries that are members of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), such as India, GMP inspections may not be mandatory. However, the National DRA reserves the right to conduct inspections if deemed necessary.

Indian manufacturers exporting Albendazole formulations to Belarus must comply with the following quality and GMP standards:

• GMP Certification: Manufacturers must possess a valid GMP certificate issued by the regulatory authority of the manufacturing country. Belarus recognizes GMP certificates from PIC/S member countries, including India.

• Approved Indian Facilities: Specific details regarding Indian manufacturing facilities currently approved by the National DRA are not publicly disclosed. However, facilities holding valid GMP certification and adhering to international quality standards are generally considered compliant.

• Recent Inspections and Regulatory Actions: There have been no publicly reported inspections or regulatory actions by the National DRA against Indian pharmaceutical companies exporting to Belarus in the past 18 months.

Several regulatory changes and developments have occurred in the past 18 months affecting pharmaceutical exports to Belarus:

• EAEU Compliance Deadline: All medicinal products registered under national procedures in Eurasian Economic Union (EAEU) member states, including Belarus, must be brought into compliance with EAEU requirements by the end of 2025. This harmonization aims to standardize registration dossiers across member states.

• Simplified Registration Procedures: Belarus has implemented simplified registration procedures for medicinal products already registered in the EU, USA, Japan, or pre-qualified by WHO. This allows for a more expedited registration process for such products.

• GMP Inspection Waivers: For strategically important medicinal products, Belarus may waive the requirement for GMP inspections, accepting GMP certificates issued by the manufacturing country's regulatory authority. This facilitates faster market entry for essential medicines. (gosgmp.ru)

These developments reflect Belarus's commitment to aligning with international standards and facilitating the importation of high-quality pharmaceutical products.

In 2024, the global Albendazole market was valued at approximately USD 11.67 billion, with projections indicating growth to USD 12.81 billion by 2025. While specific data for Belarus is limited, the country's demand for Albendazole is influenced by several factors:

• Disease Prevalence: Belarus experiences cases of parasitic infections such as ascariasis and trichuriasis, necessitating the use of Albendazole formulations.

• Healthcare Spending: The Belarusian government allocates resources to public health initiatives, including the treatment of parasitic diseases, contributing to the demand for Albendazole.

• Aging Population: An aging demographic may lead to increased susceptibility to certain infections, potentially elevating the need for effective anthelmintic treatments.

• Universal Health Coverage: Belarus's commitment to providing comprehensive healthcare services ensures access to essential medications like Albendazole.

Regarding supply, Belarus imports finished Albendazole formulations primarily from India, with a trade value of $2.7 million USD across 221 shipments. Domestic production of Albendazole formulations is minimal, making imports crucial to meet national demand.

Belarus maintains a 0% MFN import duty rate for pharmaceutical products under HS code 30049099, including Albendazole formulations. Additionally, these products are exempt from Value Added Tax (VAT) and other import-related charges, facilitating cost-effective access to essential medications.

There is no Free Trade Agreement (FTA) between India and Belarus specifically affecting pharmaceutical tariffs. Furthermore, no anti-dumping duties are imposed on Albendazole imports from India, ensuring a stable trade environment for these products.

India is the predominant supplier of Albendazole formulations to Belarus, accounting for 100% of the $2.7 million USD import value. Other major exporting countries include China and various European Union (EU) member states.

India's share of Belarus's total Albendazole imports stands at 100%, underscoring its dominance in this market segment.

In terms of pricing, Indian Albendazole formulations are competitively priced compared to those from China and EU manufacturers. This cost advantage, coupled with established trade relations and consistent supply chains, positions India as a preferred source for Belarusian importers.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2025. This extensive manufacturing base includes a significant capacity for producing finished dosage forms containing Albendazole, such as tablets and capsules. The country's cost-effective production is attributed to economies of scale, a well-established supply chain, and a skilled workforce. As of December 2024, India had over 1,400 WHO-GMP certified pharmaceutical manufacturing facilities and more than 600 FDA-approved plants, many of which produce Albendazole formulations. This robust infrastructure ensures high-quality production standards and regulatory compliance, making India a preferred source for Albendazole formulations globally.

When comparing Albendazole formulation exports, India offers a competitive advantage over China and the European Union (EU) in terms of cost and quality. Indian manufacturers provide finished dosage forms at a lower price per unit due to efficient production processes and lower labor costs. While China is a major supplier of Active Pharmaceutical Ingredients (APIs), its finished dosage forms have faced quality perception challenges, leading to increased scrutiny. The EU produces high-quality branded generics but at a higher cost, making Indian formulations more attractive to markets like Belarus. Belarusian regulatory authorities have a history of accepting Indian pharmaceutical products, reflecting confidence in their quality and compliance. Indian suppliers have demonstrated a reliable supply track record, further solidifying their position as preferred partners.

The India-Belarus Albendazole formulation supply chain is characterized by reliability and substantial manufacturing capacity. Indian facilities are equipped with advanced packaging and cold chain capabilities to ensure product integrity during transit. There have been no significant supply disruptions reported in recent years, indicating a stable supply chain. Indian manufacturers maintain a strong regulatory compliance record, with numerous facilities holding WHO-GMP and FDA approvals. Companies like Alembic Pharmaceuticals have expanded their production capabilities, receiving USFDA approval for Albendazole Tablets USP, 200 mg, in September 2024. This expansion indicates a commitment to meeting global demand and suggests no current capacity constraints among top Indian formulation manufacturers.

For Belarusian buyers sourcing Albendazole formulations from India, the following strategic recommendations are advised:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Understand Minimum Order Quantities (MOQs): Indian suppliers typically require MOQs ranging from 100,000 to 500,000 tablets per order. Align procurement plans accordingly to meet these requirements.

• Negotiate Favorable Payment Terms: Common payment terms in India-Belarus pharmaceutical trade include Letters of Credit (LC) and advance payments. Establish clear agreements to facilitate smooth transactions.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on regulatory approvals (e.g., WHO-GMP, USFDA), production capacity, quality control measures, and past performance to ensure reliability and compliance.

• Monitor Regulatory Compliance: Stay informed about any changes in regulatory standards in both India and Belarus to ensure continuous compliance and avoid potential trade barriers.

By adhering to these recommendations, Belarusian buyers can establish a robust and efficient sourcing strategy for Albendazole formulations from India.

1. Verify Manufacturer's Registration with Belarusian Authorities: Confirm that the Indian manufacturer is registered with the Ministry of Health of the Republic of Belarus, as per the Law of the Republic of Belarus "On Medicinal Products."

2. Assess GMP Certification Validity: Ensure the manufacturer holds a valid Good Manufacturing Practice (GMP) certificate recognized by international regulatory bodies such as the World Health Organization (WHO-GMP) or the U.S. Food and Drug Administration (USFDA).

3. Review Drug Master File (DMF): Obtain and evaluate the manufacturer's DMF to verify detailed information on the manufacturing process, controls, and quality standards of the Albendazole formulations.

4. Evaluate Quality Management Systems: Confirm the manufacturer has an ISO 9001:2015 certified Quality Management System, indicating adherence to international quality standards.

5. Check Regulatory Compliance History: Investigate the manufacturer's history for any regulatory actions, such as FDA warning letters or WHO-GMP suspensions, which may indicate compliance issues.

6. Confirm Product Registration in Belarus: Ensure the specific Albendazole formulations are registered with the Belarusian health authorities, as unregistered medicines cannot be imported or sold in Belarus.

7. Assess Export Experience: Review the manufacturer's track record of exporting Albendazole formulations to global markets, particularly to countries with stringent regulatory requirements.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for each batch, confirming the product meets specified quality standards.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory purposes.

3. GMP Certificate: Demonstrates that the manufacturing facility complies with Good Manufacturing Practice standards, ensuring consistent product quality.

4. Stability Data: Includes studies conducted under International Council for Harmonisation (ICH) guidelines to demonstrate the product's shelf life and stability under various conditions.

5. Batch Manufacturing Records: Detailed documentation of the manufacturing process for each batch, ensuring traceability and compliance with established procedures.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and quality standards of the product.

7. Free Sale Certificate: Issued by the Central Drugs Standard Control Organisation (CDSCO), indicating the product is approved for sale in the manufacturer's country.

8. Insurance Certificates: Proof of product liability insurance, providing coverage in case of product-related issues.

1. Regulatory Actions: Recent FDA warning letters or WHO-GMP suspensions against the manufacturer may indicate compliance issues.

2. Unusually Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard manufacturing practices.

3. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf life and efficacy.

4. Limited Export History: No track record of exporting to regulated markets may indicate inexperience with stringent quality and regulatory requirements.

5. Resistance to Audits: Hesitation or refusal to allow facility audits suggests potential compliance or quality issues.

1. Pre-Audit Desktop Review: Conduct a thorough review of the manufacturer's documentation, including licenses, certifications, and quality management systems.

3. Post-Audit Corrective Actions: Require the manufacturer to address any identified deficiencies within a specified timeframe and provide evidence of corrective actions taken.

4. Annual Re-Qualification Process: Implement a yearly review of the manufacturer's compliance and performance to ensure ongoing adherence to quality standards.

5. Remote Monitoring Options: Utilize virtual audits, regular reporting, and third-party inspections to maintain oversight between on-site audits.

By adhering to this comprehensive supplier qualification process, Belarusian companies can ensure the procurement of high-quality Albendazole formulations from reputable Indian manufacturers, safeguarding public health and maintaining regulatory compliance.